Uses
A-966492 effectively inhibits PARP-1 with an EC50 of 1 nM and a Ki value of 1 nM. When it acts on PARP-2, the Ki value is 1.5 nM. It has excellent efficacy on PARP enzyme, especially on C41 cells. A-966492 significantly enhanced the effect of TMZ in a dose-dependent manner.
Biological Activity
a-966492 is an inhibitor of parp-1 with ki value of 1nm [1].parp-1 belongs to the poly(adp-ribose) polymerases (parps) family, it contributes to the resistance happened after cancer therapy. a-966492 is a potent inhibitor of both parp-1 and parp-2 (ki value of 1.5nm) with good potency in c41 whole cells (ec50 value of 1nm). a-966492 shows excellent pharmaceutical properties with oral bioavailabilities of 34-72% and half-lives of 1.7-1.9 h. additionally, a-966492 can crosses the blood-brain barrier. a-966492 is proved potent in a murine b16f10 syngeneic melanoma model and a brca1-deficient mx-1 breast carcinoma model. meanwhile, it can enhance the efficacy of tmz and carboplatin in these models [1].
in vivo
A-966492 demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with temozolomide and in an MX-1 breast cancer xenograft model both as a single agent and in combination with carboplatin. In addition, A-966492 has excellent pharmaceutical properties and has demonstrated in vivo efficacy in preclinical mouse tumor models in combination with TMZ and carboplatin, as well as single agent activity in a BRCA1-deficient MX-1 tumor model. A-966492 is further characterized in Sprague Dawley rats, beagle dogs, and cynomolgus monkeys, with A-966492 demonstrating oral bioavailabilities of 34 72% and half-lives of 1.7 1.9 hours. In vivo, A-966492 demonstrates significant enhancement of the efficacy of TMZ in a murine B16F10 syngeneic melanoma model, with the A-966492 combination groups showing superior efficacy[1].
References
[1] penning td, zhu gd, gong j, thomas s, gandhi vb, liu x, shi y, klinghofer v, johnson ef, park ch, fry eh, donawho ck, frost dj, buchanan fg, bukofzer gt, rodriguez le, bontcheva-diaz v, bouska jj, osterling dj, olson am, marsh kc, luo y, giranda vl. optimization of phenyl-substituted benzimidazole carboxamide poly(adp-ribose) polymerase inhibitors: identification of (s)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1h-benzimidazole-4-carboxamide (a-966492), a highly potent and efficacious inhibitor. j med chem. 2010 apr 22;53(8):3142-53.
